

AUDIOLOGY

Idiopathic sensorineural hearing loss in the only hearing ear

Ipoacusia neurosensoriale idiopatica nell'unico orecchio udente

S. BERRETTINI^{1,2}, A. DE VITO¹, L. BRUSCHINI¹, S. FORTUNATO¹, F. FORLI¹

¹ ENT, Audiology and Phoniatics University Unit of "Azienda Universitaria Ospedaliera Pisana" Pisa, Italy; ² Guest Professor at Division of ENT Diseases, Karolinska Institutet, Stockholm, Sweden

SUMMARY

A retrospective chart review was used for 31 patients with sudden, progressive or fluctuating sensorineural hearing loss (SHL) in the only hearing ear who had been consecutively evaluated at the ENT, Audiology and Phoniatics Unit of the University of Pisa. The group of patients was evaluated with a complete history review, clinical evaluation, imaging exam (MRI, CT), audiologic tests (tone and speech audiometry, tympanometry, study of stapedial reflexes, ABR and otoacoustic emission) evaluation. In order to exclude genetic causes, patients were screened for CX 26 and CX30 mutations and for mitochondrial DNA mutation A1555G. Patients with sudden or rapidly progressive SHL in the only hearing ear were treated with osmotic diuretics and corticosteroids. In patients who did not respond to intravenous therapy we performed intratympanic injections of corticosteroid. Hearing aids were fitted when indicated and patients who developed severe to profound SHL were scheduled for cochlear implant surgery. The aim of this study is to report and discuss the epidemiology, aetiopathogenesis, therapy and clinical characteristic of patients affected by SHL in the only hearing ear and to discuss the issues related to the cochlear implant procedure in some of these patients, with regard to indications, choice of the ear to implant and results.

KEY WORDS: Sensorineural hearing loss • Only hearing ear • Progressive sensorineural hearing loss • Cochlear implant

RIASSUNTO

Uno studio retrospettivo è stato condotto su 31 pazienti, giunti all'osservazione della clinica ORL Audiologia e Foniatria dell'Università di Pisa dal 2007 al 2013, affetti da ipoacusia neurosensoriale improvvisa, fluttuante o progressiva nell'unico orecchio udente. L'intero gruppo di pazienti è stato valutato con una adeguata anamnesi, otomicroscopia, esami di imaging (TC RMN), test audiologici (audiometria tonale e vocale, impedenziometria, potenziali evocati uditivi e otoemissioni acustiche). Questo gruppo di pazienti è stato sottoposto anche a una valutazione genetica (ricerca mutazioni CX 26, CX 30 e DNA mitocondriale A1555G) e a test di laboratorio. I pazienti con ipoacusia improvvisa o rapidamente progressiva sono stati trattati con diuretici osmotici e corticosteroidi (endovena o intratimpanici). I pazienti che non hanno recuperato in maniera adeguata dopo il trattamento sono stati avviati a un percorso di protesizzazione. Nei pazienti con insufficiente resa protesica sono stati sottoposti ad impianto cocleare. Lo scopo di questo studio è quello di discutere l'epidemiologia, l'eziopatogenesi e le caratteristiche cliniche di pazienti affetti da ipoacusia neurosensoriale nell'unico orecchio udente e inoltre discutere le indicazioni e la scelta dell'orecchio da impiantare in questa categoria di pazienti.

PAROLE CHIAVE: *Ipoacusia neurosensoriale • Unico orecchio udente • Ipoacusia progressiva • Impianto cocleare*

Acta Otorhinolaryngol Ital 2016;36:119-126

Introduction

Patients suffering from severe to profound unilateral sensorineural hearing loss (SHL) in one ear can develop idiopathic SHL in the contralateral ear after a period varying from months to years. This condition may be sudden, progressive or fluctuating. The development of SHL is a dramatic event leading patients with an only hearing ear to be confused, worried, anxious and isolated from the surrounding world, and thus worthy of special consideration. This small sub-population of patients becomes practically deaf, so that SHL in the only hearing ear is an audiologic emergency. So far, it has not been possible to provide any specific therapy, while

steroids, vasodilators and diuretics are frequently prescribed. Cochlear implants are often the last resort to rehabilitate these patients when medical therapy and hearing aids do not result in satisfactory hearing performance.

We believe it is of interest to investigate the clinical characteristics of this specific group of patients because the scientific literature describing this "disease" is relatively limited. To our knowledge, the aetiopathogenesis and incidence of this clinical condition have never been previously reported. There are only a few studies reporting on sudden SHL¹⁻⁴ in the only hearing ear, but none describing the progressive forms of the disease.

In this regard, delayed endolymphatic hydrops (DEH) is

a clinical entity that may present with features similar to SHL in the only hearing ear. This disease, first reported by Nadol et al. in 1975⁵, is characterised by the early onset of profound or total SHL in one ear. After a prolonged period of stagnation, a late phase of the disease appears with different otologic symptoms that can be described as two main types of DEH: ipsilateral and contralateral variants. Ipsilateral DEH appears with episodic vertigo in the deaf ear, while contralateral DEH appears as fluctuating hearing loss and/or episodic vertigo in the previously normal ear. In contralateral DEH, the SHL first affects the low-tone frequencies and is always fluctuating⁶.

In this paper, we report on a retrospective case series of 34 patients (collected over 6 years) with one deafened ear – as a result of various causes – who subsequently developed progressive, fluctuating or sudden SHL in the contralateral ear. The aim is to present and discuss epidemiology, aetiopathogenesis and clinical characteristics of patients affected by SHL in the only hearing ear and to discuss the issues related to the cochlear implant procedure in these patients with regards to indications, choice of the ear to implant and results.

Materials and methods

A retrospective chart review was used for 34 patients with SHL in the only hearing ear who had been consecutively evaluated at the Ear, Nose and Throat (ENT) Audiology and Phoniatrics Unit of the University of Pisa (tertiary referral centre for audiological disease) between January 2007 and January 2013. The sample was composed of 19 men and 15 women. All data were collected after receiving informed consent by all patients involved and according to the Declaration of Helsinki. All patients were evaluated with a complete history review (with particular attention to family history and other systemic diseases). Patients underwent otomicroscopy, pure tone audiometry, speech audiometry, tympanometry and study of stapedial reflexes. All patients were also evaluated with auditory brainstem responses and otoacoustic emissions. Patients who complained of dizziness underwent vestibular examination with videonystagmography.

Several blood tests were carried out to exclude any known cause of hearing loss (complete blood cell count, general chemistry screen, VES, PCR, mucoproteins, fibrinogen, urine test, total and fractionated protein, bilirubin, vGT, LDH, SGOT, SGPT, CPK, TSH, T3, T4, serological tests for toxoplasmosis, syphilis, borrelia burgdorferi, antibodies ANA, ENA, AMA, ASMA, CLIF test, ANCA). In order to exclude genetic causes, patients were screened for connexin 26 and connexin 30 mutations and for the most frequent mitochondrial DNA mutation related to deafness (A1555G). Patients were also evaluated with 1.5–3.0 Tesla contrast-enhanced magnetic resonance imaging (MRI) of the brain, cerebellopontine angle and inner ear. The study

protocol of the inner ear includes a thin slice heavily T2W 3D sequence (FIESTA) to stress the signal difference between the cerebrospinal fluid (CSF) and other tissues, and thin axial and coronal SE or FSE 2D T1W with and without gadolinium administration. Axial FLAIR imaging was performed, which covered the entire brain. All patients underwent CT scan of petrous bone to exclude advanced otosclerosis, perilymphatic fistulas or other bone pathologies. Patients with a history of hypertension or cardiovascular disease were also evaluated with colour Doppler ultrasound of neck vessels.

Patients with known autoimmune diseases, vascular diseases, diabetes and other metabolic systemic diseases were excluded.

Out of 34 patients three were excluded: one because of the presence of a mutation in the connexin 26 gene (M34T), another for an enlarged bilateral vestibular aqueduct (EVA) and one because of the presence of superficial hemosiderosis of the central nervous system. This patient experienced unilateral profound deafness after a head trauma with a temporal bone fracture and some years later developed fluctuating progressive SHL in the contralateral ear⁷.

In 18 of the 31 patients included, the aetiology of SHL in the first deafened ear was unknown and was defined as idiopathic; in 6 patients SHL was due to ear surgery (1 patient with translabyrinthine surgery for acoustic neuroma; in 5 patients deafness was due to tympanoplasty for cholesteatoma or middle ear chronic otitis with postoperative severe or profound SHL). In another patient SHL was subsequent to a head trauma with a temporal bone fracture. An infectious aetiopathogenesis (bacterial meningitis, acute otitis media, systemic viral infection etc.) was recognised in another 6 cases.

Idiopathic SHL occurring in the second affected ear was classified as follows:

- *progressive*: SHL ≥ 15 dB HL (PTA at 0.5–1–2–4 kHz) occurring in a 10-year period⁸;
- *sudden*: abrupt hearing deterioration of ≥ 30 dB HL in at least 3 consecutive frequencies occurring in a period no longer than 3 days⁹;
- *progressive-fluctuating*: recurrent episodes of SHL of any entity that recover rapidly.

The entire group of patients was evaluated by the same audiological team and submitted to the battery of audiological tests that we routinely use to evaluate patients with progressive, fluctuating or sudden SHL (Table I).

Patients with sudden or rapidly progressive SHL in the only hearing ear were treated with glycerol 10% 500 ml/day i.v. for 7 days, methylprednisolone 250 mg/day for 3 days, and then tapered for a 15-day period and a proton pump inhibitor (lansoprazole 30 mg/die) was added. In patients who did not respond to intravenous therapy we performed intratympanic injections of dexamethasone (4 mg/ml 3 injections for 10 days). Hearing aids were fitted

Table I. Protocol of clinical evaluation for SHL in the only hearing ear.

Auditory test	Tonal and speech audiometry
	Tympanometry study of stapedial reflex
	ABR and otoacoustic emission
	Auditory skills test
Laboratory test	Blood count
	Glucose, cholesterol, triglycerides
	Creatinine, blood urea nitrogen, electrolytes
	Total protein and fractionated
	Bilirubin, vGT, LDH, SGOT, SGPT, CPK
	TSH, T3, T4
	Urine test
	Serological tests for toxoplasmosis, syphilis, <i>Borrelia burgdorferi</i>
	ESR, CRP, mucoproteins, fibrinogen
	Antibodies: ANA, ENA, AMA, ASMA, CLIF test
	ANCA, anti-collagen type II, antiphospholipids
Genetic test	Mutation of CX 26 and 30
	Mitochondrial DNA (A1555G)
Imaging test	3.0 Tesla MRI
	CT
	Colour Doppler of neck vessels
Specialist evaluation	Neurological
	Rheumatologic

when indicated and patients who developed severe to profound SHL were scheduled for cochlear implant surgery.

Results

The mean age of patients when SHL occurred in the first ear was 28.09 years (age range 0-62 years). The mean pure tone average (PTA between 0.5 kHz and 1 kHz, and 2 kHz) in the first deafened ear was 82.03 dB (range 70 dB-120dB). SHL occurred in the contralateral ear after a mean period of 25.09 years (age range 2-57 years). The onset of SHL in the contralateral ear was sudden in 12 patients, progressive in 13 cases and progressive with fluctuations in another 6 cases.

With regards to the hearing threshold curve in the second affected ear, 18 patients developed downsloping SHL, 4 patients upsloping SHL and the last 9 patients a flat curve SHL. The mean mean pure tone audiometry (PTA) in the second ear that developed a hearing loss was 42.03 dB (range 30-120 dB) (Table II).

Eleven of 31 patients complained monolateral tinnitus (only in the first ear interested by SHL), while 20 of 31 complained of bilateral tinnitus. Four of 31 patients complained of occasional and non-recurrent vertigo, not temporally related to the development of SHL.

Of the 18 patients with sudden or rapidly progressive SHL in the second ear, 5 (# 1, 7, 18, 25, 26) were treated with the above-mentioned mentioned protocol; the remaining

13 patients referred to our clinic over 6 months after the onset of SHL and with no indications to medical treatment. In these patients, the mean PTA before therapy was 59.6 dB and 47.6 dB after therapy with a mean improvement of 12.0 dB.

Hearing aids fitting in the best hearing ear, or bilaterally when indicated, was proposed to 25 of 31 patients. In 17 of 25 patients, hearing performance were good: mean open-set speech-recognition score in silence was 78.8% (range 60-100%). While in 8 of 25 patients (# 3, 8, 11, 27, 28, 29, 30, 31) the hearing performance with hearing aids was very poor (mean open-set speech-recognition score in silence 25.6%, range 0-45%), and cochlear implant surgery was proposed. Patients 3 and 11 declined the cochlear implant (CI) procedure. The remaining 6 patients were implanted by using a Nucleus Contour Advance CI24RE (Cochlear) (Table III). Of a group of 184 patients (both children and adults), 6 were implanted in the same period (2007-2013). All patients were operated by the same surgical team and the final insertion of the CI was performed by the same senior surgeon. The array of electrodes was fully inserted in all cases. A post-operative X-ray of the skull was performed to confirm the correct placement of the implant. Five of six patients were implanted in the second deafened ear, while one patient (# 8) was implanted in the first deafened ear. The mean preoperative open-set speech-recognition score in silence was 20% (range 0-40%). The mean post-operative score (Table III), measured 1 year after the switch-on of the implant, was 83% (range 70-100%) with a significant improvement in hearing performance.

Discussion

Epidemiology

To our knowledge, there are no papers in the literature reporting epidemiologic data of idiopathic SHL in the only hearing ear.

Few reports^{1,2,10,11} on sudden SHL in the only hearing ear have been published. Stahl and Cohen² reported that 20% of patients with sudden SHL were deaf in the contralateral ear (9 of 45 patients), while Lee et al.¹ reported a percentage of 11.5% (25 out of 217 patients). Fetterman et al.¹² found that 1.7% of patients (14/823 patients) with sudden SHL had bilateral loss. Shaia and Sheehy¹¹ reported 1,220 cases of sudden SHL observed at the House Ear Clinic from 1964 to 1972, 4% of which were bilateral. Half of their cases occurred simultaneously while the others were sequential. Therefore, the occurrence of sudden SHL seems to be a rather common event in patients with only one hearing ear, and more frequent than sudden SHL in the normal population, which is reported to be 5 to 160 per 100,000¹³⁻¹⁴. Concerning the involvement of the only hearing ear, patients with progressive or fluctuating SHL (19/31 or 61% in our sample) should be added to patients

Table II. Patients and clinical characteristics.

	Age	Age of first SHL	Aetiology first SHL	Age SHL contralateral ear	PTA first ear	PTA second ear	Development SHL in the second ear	Audiometric curve
1	45	18	Idiopathic	42	73	80	Sudden	Downsloping
2	50	28	Idiopathic	50	78.3	60	Fluctuating	Downsloping
3	76	61	Surgery for neuroma	63	120	80	Progressive	Downsloping
4	32	5	Infective	30	120	70	Fluctuating	Downsloping
5	62	38	Idiopathic	52	87	90	Progressive	Downsloping
6	70	60	Idiopathic	69	70	30	Progressive	Upsloping
7	69	55	Infective (OMC)	57	120	50	Sudden	Downsloping
8	57	41	Idiopathic	52	120	80	Progressive	Downsloping
9	36	15	Idiopathic	34	120	32.5	Fluctuating	Upsloping
10	75	14	Surgery for OMC	65	95	65	Progressive	Downsloping
11	75	14	Trauma	65	120	100	Progressive	Pantonal
12	60	5	Infective	60	70	57	Sudden	Downsloping
13	72	62	Surgery for OMC	72	73	63	Sudden	Downsloping
14	66	9	Infective	65	120	50	Progressive	Upsloping
15	72	33	Surgery for OMC	70	110	45	Progressive	Downsloping
16	71	47	Surgery for OMC	52	90	86.25	Progressive	Pantonal
17	61	6	Surgery for OMC	54	120	47.5	Fluctuating	Downsloping
18	53	1	Infective	38	112.5	40	Sudden	Downsloping
19	64	62	Idiopathic	64	82.5	70	Sudden	Downsloping
20	45	1	Idiopathic	38	120	58.75	Sudden	Downsloping
21	65	48	Idiopathic	57	120	77.5	Sudden	Downsloping
22	29	2	Infective	16	120	35	Sudden	Upsloping
23	22	0	Idiopathic	21	120	46.7	Progressive	Pantonal
24	58	4	Idiopathic	29	116.7	50	Progressive	Pantonal
25	68	48	Idiopathic	63	90	35	Fluctuating	Pantonal
26	44	0	Idiopathic	42	105	33	Fluctuating	Downsloping
27	74	14	Idiopathic	71	120	73.3	Sudden	Downsloping
28	65	60	Idiopathic	65	81.6	120	Sudden	Pantonal
29	69	40	Idiopathic	66	120	78.3	Progressive	Pantonal
30	70	60	Idiopathic	69	113.3	76.6	Sudden	Pantonal
31	65	20	Idiopathic	58	98.3	101.6	Progressive	Pantonal
32	52	20	M34T	41	115	45	Progressive	Pantonal
33	45	6	EVA	15	80	40	Fluctuating	Pantonal
34	75	50	Trauma _ SS	70	120	52.5	Progressive	Downsloping

Table III. Patient who underwent a CI procedure.

Patient n	Ear implanted: 1 st ear or 2 nd ear	Auditory skills test recognition open-set bisyllabic word in silence	Use of bimodal hearing stimulation	Time from onset of HL in the implanted ear	Use of hearing aid in the ear implanted before surgery
8	1 st	70% (100% IC+HA)	Yes	16 years	Yes (for 5 years)
27	2 nd	85%	No	3 years	Yes (for 2 years)
28	2 nd	80%	Yes	3 months	No
29	2 nd	75%	No	3 years	Yes (for 1 year)
30	2 nd	100%	No	2 months	No
31	2 nd	90%	No	6 years	Yes (for 4 years)

affected by sudden SNHL. This has led us to think that the development of SHL in the two ears is not an independent event, but that it could be related to aetiopathogenetic factors.

We believe that the possibility of developing SHL in the only hearing ear is not a negligible fact and that further epidemiologic studies should be conducted in this particular group of patients to better understand the risks for patients with an only hearing ear to develop SHL in the contralateral ear.

Aetiology

The aetiological study of hearing loss is greatly important for both comprehensive treatment of disease and prognosis. The aetiology of this condition has been the subject of numerous reports in the literature, but to our knowledge no data are available concerning the aetiology of hearing loss in patients with an only hearing ear. In the past years our group has made a great effort to investigate the aetiology of hearing loss, in particular of progressive SHL and, as previously described⁸, we have defined the following causes: genetic mutations, inner ear malformations, infectious diseases, autoimmune disease, neoplastic, trauma, etc. Patients with hearing loss, especially those with an only hearing ear should be submitted to accurate and comprehensive aetiologic evaluation to investigate a possible correlation between the aetiology and the risk of developing a contralateral SHL.

Despite the comprehensive aetiological study in our patients, the aetiology of SHL in the only hearing ear remains unknown in a high percentage of these patients (31/34 patients, 91%). Therefore, we defined the disease as idiopathic and can only make some hypotheses on its origins.

A first hypothesis is genetic: unknown genetic mutations might lead to the development of SHL, possibly with a time lapse between the two ears.

A second hypothesis is the presence of microscopic osseous or membranous labyrinth malformations that are not visible at the resolution of our diagnostic tools. The most recent imaging techniques have revealed inner ear malformations in a relevant percentage of patients affected by SHL. The data, reported in the scientific literature, mainly concern the paediatric population with a reported prevalence of inner ear malformations in children with profound SHL between 14-30%¹⁵. However, minor malformations or malformations limited to the membranous labyrinth, not detectable with common diagnostic tools, may be responsible for some cases of SHL of unknown origin.

A third hypothesis is the viral one. Some authors have hypothesised two different possibilities in the development of SHL by viral damage. Schuknecht et al.¹⁶ explained the genesis of DEH, and hypothesised a praecox viral labyrinthopathy leading to early cochleo-vestibular

damage in one ear with subsequent delayed hydrops in the contralateral ear due to an alteration of endolymph production and resorption. Other authors¹⁷ have considered that a praecox viral infection could be responsible for SHL in the first ear and then a delayed reactivation of the same virus could cause SHL in the second ear. They found the genome cytomegalovirus (CMV) within the cochlea of a deaf patient with no evidence of acute infection. The presence of this virus suggested a possible role in inner ear injury through reactivation of the latent virus within the cochlea.

A final possible hypothesis is the autoimmune one. To explain the genesis of DEH, our group¹⁸ hypothesised that contralateral hydrops could be mediated by an autoimmune process. We found a non-specific immunological pattern that was altered in 50% of patients with DEH and was significantly higher than in patients affected by Ménière's disease. A similar hypothesis is that SHL in the contralateral ear may be caused by an autoimmune mechanism involving recirculating memory cells sensitised against cochlear tissues. A comparable mechanism is described in ophthalmology, which is called sympathetic ophthalmia¹⁹ in which there is an inflammatory reaction in the healthy eye after a traumatic destruction of the other eye. The pathologic mechanism could be explained as follows: during an infection, trauma, or surgery there is exposure of anatomically sequestered proteins of the inner ear. These proteins, recognised as 'foreign', serve as antigens, and result in the induction of lymphocytes. These cells re-circulate as memory cells and reach the intact contralateral cochlea, thus leading to immune response and damage of the organ. In 1994, Gloddek et al.²⁰ described an animal model of this "sympathetic cochleo-labyrinthitis". They found a high percentage of sensitised lymphocytes on the apical turn of the cochlea that is not in agreement with the clinical findings herein, since the patients examined in this study (18/31) mainly showed a downsloping audiometric curve.

Clinical issues and therapies

In reviewing the literature, we found a number of studies reporting patients with sudden SHL in the only hearing ear and describing their clinical features, treatment and results (Table IV)¹⁻⁴. The samples¹⁻⁴ (Table IV) were heterogeneous and the therapy protocols were different, so that it was difficult to compare the results and efficacy of the therapies.

In 2006, Stahl and Cohen² reported 9 cases of patients affected by sudden SHL in the only hearing ear, and described the clinical characteristics of patients and features of the hearing threshold curve. The authors treated patients with prednisolone 60-80 mg/day, who achieved a mean improvement of 9 ± 8.7 dB in the three main affected frequencies. Stahl and Cohen² concluded that patients affected by a sudden SHL in the only hearing ear might

Table IV. Studies reporting patients with sudden SHL in the only hearing ear.

Article	Year	Patients	Aetiology of 1 st ear HL	Development of 2 nd ear HL	Type of audiometric curve in the 2 nd ear	Treatment	Cochlear implant
Stahl and Cohen	2006	9	-	Sudden	4 Downsloping 5 Upsloping	Prednisolone 60-80 mg/day	-
Lee et al.	2010	25	12 idiopathic 7 Inflammatory 2 Trauma 1 Acoustic Schwannoma 2 AVL	Sudden	-	Prednisolone 1-1.15 mg/kg/day tapered MgSO ₄ (4 g/day) Dextran (10 ml/kg in 5% dextrose) Carbogen Inhalation Intratympanic injection if no recovery	6
Hawkings	2008	1	Congenital	Sudden	Pantonal	Oral steroids	-
Pykko et al.	1997	10	6 Ménière 1 Cogan 3 Idiopathic	2 Sudden 1 Fluctuating 7 Progressive	-	Azathioprine (25 mg tid) Prednisolone (5-15 mg/day) after initial dose of 20-40 mg	

receive the same treatment with corticosteroids as other patients affected by sudden SHL.

Pykko et al.⁴ reported on 10 cases of patients, 6 of whom were affected by Ménière's disease, one by Cogan's syndrome and 3 by idiopathic SHL; they treated patients with corticosteroids and immunosuppressants, and hypothesised an autoimmune genesis of SHL in the contralateral ear. Patients were treated with azathioprine (25 mg tid) and prednisolone (5-15 mg/day) after an initial dose of 20-40 mg and reported a mean improvement of 22.4 dB.

Lee et al.¹ disposed of a larger case series of 24 patients and were the only authors reporting on patients who had undergone cochlear implantation. They treated patients with prednisolone 1-1.15 mg/kg/day tapered, MgSO₄ (4 g/day), Dextran (10 ml/kg in 5% dextrose), Carbogen inhalation and corticosteroid intratympanic injection if there was no improvement. A recovery rate of 64% was reported.

We treated our group of patients with the following therapeutic protocol: glycerol 10% 500 ml/day i.v. for 7 days, methylprednisolone 250 mg/day for 3 days then tapered for a 15-day therapy and a proton pump inhibitor (lansoprazole 30 mg/day)²¹. Patients who did not respond to intravenous therapy after 7 days were submitted to 3 intratympanic injections of dexamethasone (4 mg/ml) in 10 days.

We treated only 5 (# 1, 7, 18, 25, 26) of 18 patients with sudden or rapidly progressive SHL because the remaining 13 patients had referred to our clinic with a time-lapse that was longer than 6 months from the onset of SHL in the second ear, and there were no indications about medical treatment. Mean PTA improvement in treated patients was 12.0 dB [range 0-24 dB]. These results are similar to those found by other authors².

The treatment of sudden idiopathic SHL is debated in the literature and there is currently no evidence of its efficacy.

Recent clinical guidelines²² suggest to use only corticosteroids (oral, iv, or intratympanic) as first line therapy and eventually hyperbaric oxygen therapy. Guidelines discourage clinicians from using pharmacologic agents (antivirals, thrombolytics, vasodilators, vasoactive substances, antioxidants) that may have side effects and no documented efficacy. The guidelines also recommend the use of intratympanic injection of corticosteroids as a salvage therapy. In this specific group of patients, we decided to add glycerol to the therapeutic protocol, owing to the analogies between idiopathic SHL in the only hearing ear and contralateral-type DEH. Diuretics significantly improve the hearing of patients with this type of DEH²³.

Outcomes of CI procedure in patients with SHL in the only hearing ear

CI is a viable option for patients whose hearing deficit becomes bilaterally severe to profound and who no longer benefit from hearing aids.

Only one paper¹ reported on patients with idiopathic SHL in the only hearing ear that underwent a CI procedure. Six of 25 patients were submitted to CI; the results in terms of reaching the top of the category of auditory performances (CAP) defined as 'use of telephone with known speaker' were good. All these patients were implanted in the second ear that developed SHL. The time necessary to reach CAP was linked to the time of auditory deprivation in the second ear. The authors concluded that a treatment like CI might be considered as early as 3 months so that the patient can return to daily verbal communication.

In our group, 6 of 31 patients underwent a CI procedure; 5 of 6 were implanted in the second ear that developed SHL, and consequently with a shorter deprivation. The hearing performances were very good in all these patients with a mean of 87.5% [range 75-100%] of post-operatively disyllabic word recognition scores.

Only one patient was implanted in the first ear that developed SHL. This choice was due to the fact that the hearing threshold was significantly better in the second deafened ear (so as to allow the use of a hearing aid, even if with partial results), and also to the fact that the first ear had a history of slight progressive SHL with long term use of a hearing aid. The auditory performances with CI only were good and satisfactory even in this patient, but lower than in the previously reported 6 patients (70% recognition of bisyllabic words). However, with bimodal stimulation the patient reached 100% of the recognition score. Moreover, he reported good satisfaction with the implant and benefits in the quality of life.

In patients with bilateral severe to profound SHL, candidates for a CI procedure, the criteria employed for the choice of the ear to implant has changed over the years. If residual hearing in one ear is suitable for hearing aid fitting, implantation in the worse ear is preferred to allow bimodal stimulation. If none of the ears is good for HA fitting, it is usually recommended to implant the ear with less hearing deprivation. Hearing deprivation is one of the stronger predictors of CI outcome in adults with post-verbal hearing loss.

However, in the literature there is no clear agreement on the choice of the side to implant in patients with monoaural sound deprivation. Several authors²⁴⁻²⁵ have reported that implanting the ear with a longer deprivation did not appear to have a negative impact on CI outcome. Notwithstanding, the UK Cochlear Implant Study Group²⁶ argued that CI was less effective in the ear with a longer deprivation even if residual hearing is better.

Recently, Boisvert et al. 2012²⁷ examined speech recognition results in 30 adults with bilateral SHL using only one hearing aid. Fifteen received the implant in the sound-deprived ear and 15 in the aided ear. The authors concluded that there was no significant difference in speech recognition results for the 2 groups when the patient in the group with CI in the sound deprived ear were tested with bimodal stimulation.

Among the 6 patients of our sample submitted to CI, 5 were not suitable for HA fitting, and the second deafened ear was implanted with good results. We decided to implant the remaining one patient on the first deafened ear, because the second ear was suitable for HA fitting.

Conclusions

Herein, we focus our attention on progressive, sudden or fluctuating SHL in the only hearing ear. SHL occurrence is not negligible and it would be important to better understand the risk for patients with an only hearing ear to develop SHL in the contralateral one.

We believe a comprehensive diagnostic protocol is mandatory to investigate all known causes of hearing loss (ear malformations, genetic anomalies, superficial siderosis,

etc.) and, if possible, to prevent contralateral involvement. Further studies should be conducted in the aetiology, epidemiology and aetiopathogenesis, because at present only hypotheses (genetic, micro-malformation, autoimmune, viral) can be made regarding the genesis of SHL in the only hearing ear.

HA fitting may not be simple for the progression or fluctuation of hearing loss over time, and therefore CI may be indicated in patients that developed a bilateral severe to profound SHL. According to literature data, the results of our patients submitted to CI are satisfactory. Our data (even if the sample is small) seem to indicate that better results can be expected in patients implanted in the ear with a shorter deprivation. Good results can be also achieved in patients implanted in the first deafened ear by using bimodal stimulation.

References

- 1 Lee SS, Ho Cho H, Ho Jang C, et al. *Fate of sudden deafness occurring in the only hearing ear: outcomes and timing to consider cochlear implantation*. J Korean Med Sci 2010;25:283-6.
- 2 Stahl N, Cohen D. *Idiopathic sudden sensorineural hearing loss in the only hearing ear: patient characteristics and hearing outcome*. Arch Otolaryngol Head Neck Surg 2006;132:193-5.
- 3 Hawkins DB. *Hearing rehabilitation in a patient with sudden sensorineural hearing loss in the only hearing ear*. Am Acad Audiol 2008;19:267-74.
- 4 Pyykkö I, Ishizaki H, Peltomaa M. *Azathioprine with cortisone in treatment of hearing loss in only hearing ear*. Acta Otolaryngol Suppl 1997;529:83-5.
- 5 Nadol JB Jr, Weiss AD, Parker SW. *Vertigo of delayed onset after sudden deafness*. Ann Otol Rhinol Laryngol 1975;84:841-6.
- 6 Giannoni B, Pagnini P, Vannucchi P. *Delayed endolymphatic hydrops*. [Article in Italian]. Acta Otorhinolaryngol Ital Suppl 1998;59:66-70.
- 7 Berrettini S, De Vito A, Bruschini L, et al. *Cochlear implantation in patients affected by superficial hemosiderosis of the central nervous system*. Eur Arch Otorhinolaryngol 2012;269:25-31.
- 8 Berrettini S, Piragine F. *Progressive sensorineural hearing loss: definition, classification, main etiological factors*. [Article in Italian]. Acta Otorhinolaryngol Ital Suppl 1998;59:9-12.
- 9 Zadeh MH, Storper IS, Spitzer JB, et al. *Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients*. Otolaryngol Head Neck Surg 2003;128:92-8.
- 10 Kirikae I, Matsuzaki T. *Clinical observations of bilateral sudden deafness*. Audiol Jpn 1967;10:320-5.
- 11 Shaia FT, Sheehy JL. *Sudden sensori-neural hearing impairment: a report of 1,220 cases*. Laryngoscope 1976;86:389-98.
- 12 Fetterman BL, Luxford WM, Saunders JE, et al. *Sudden bilateral sensorineural hearing loss*. Laryngoscope 1996;106:1347-50.

- ¹³ Byl FM Jr. *Sudden hearing loss: eight years' experience and suggested prognostic table*. *Laryngoscope* 1984;94:647-61.
- ¹⁴ Klemm E, Deutscher A, Mosges R. *A present investigation of the epidemiology in idiopathic sudden sensorineural hearing loss* [in German]. *Laryngorhinootologie* 2009;88:524-7.
- ¹⁵ Agarwal SK, Singh S, Ghuman SS, et al. *Radiological assessment of the Indian children with congenital sensorineural hearing loss*. *Int J Otolaryngol* 2014;2014:808759.
- ¹⁶ Schuknecht HF, Gulya AJ. *Endolymphatic hydrops. An overview and classification*. *Ann Otol Rhinol Laryngol Suppl* 1983;106:1-20.
- ¹⁷ Di Nardo W, Cattani P, Lopizzo T, et al. *Multiple viral genome search in endolabyrinthic fluids of profoundly deaf patients: possible cytomegalovirus intracochlear reactivation*. *Audiol Neurootol* 2009;14:290-5.
- ¹⁸ Casani A, Fattori B, Berrettini S, et al. *Delayed endolymphatic hydrops: an analysis of 12 cases*. [Article in Italian] *Acta Otorhinolaryngol Ital* 1993;13:297-303.
- ¹⁹ Dreyer WB, Zegarra H, Zakov ZN, et al. *Sympathetic ophthalmia*. *Am J Ophthalmol* 1981;92:816-9.
- ²⁰ Gloddek B, Rogowski M, Arnold W. *Adoptive transfer of an autoimmune labyrinthitis in the guinea pig; animal model for a sympathetic cochleolabyrinthitis* *Clin Exp Immunol* 1994;97:133-7.
- ²¹ Berrettini S, Ravecca F, Forli F, et al. *Diagnostic and therapeutic approach to progressive sensorineural hearing loss*. [Article in Italian]. *Acta Otorhinolaryngol Ital Suppl* 1998;59:87-94.
- ²² Stachler RJ, Chandrasekhar SS, Archer SM, et al. *Clinical practice guideline: sudden hearing loss*. *Otolaryngol Head Neck Surg* 2012;146:S1-35.
- ²³ Fujino K, Naito Y, Endo T, et al. *Clinical characteristics of delayed endolymphatic hydrops: long-term results of hearing and efficacy of hyperbaric oxygenation therapy*. *Acta Otolaryngol Suppl* 2007;557:22-5.
- ²⁴ Francis HW, Yeagle JD, Brightwell T, et al. *Central effects of residual hearing: implications for choice of ear for cochlear implantation*. *Laryngoscope* 2004;114:1747-52.
- ²⁵ Chen JM, Shipp D, Al-Abidi A, et al. *Does choosing the "worse" ear for cochlear implantation affect outcome?* *Otol Neurotol* 2001;22:335-9.
- ²⁶ UK Cochlear Implant Study Group. *Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults I: theory and measures of effectiveness*. *Ear Hear* 2004;25:310-35.
- ²⁷ Boisvert I, Lyxell B, Mäki-Torkko E, et al. *Choice of ear for cochlear implantation in adults with monaural sound-deprivation and unilateral hearing aid*. *Otol Neurotol* 2012;33:572-9.

Received: February 1, 2015 - Accepted: September 3, 2015